<DOC>
	<DOCNO>NCT01657318</DOCNO>
	<brief_summary>In study , investigator hypothesize use olivamine-containing product management patient compromise nonhealing low extremity ulcer feasible Philippine setting . It result complete ulcer heal wound closure 16 week .</brief_summary>
	<brief_title>Olivamine-containing Products Management Patients With Nonhealing Lower Extremity Ulcers</brief_title>
	<detailed_description>The specific aim study assess feasibility use olivamine-containing product management patient compromise nonhealing low extremity ulcer Philippines . The primary endpoint evaluate efficacy Olivamine healing chronic low extremity ulcer assess rate change ulcer size ( wound heal trajectory ) proportion complete ulcer healing ( wound closure ) 4 , 8 , 16 16 week compare baseline , week 0 .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Skin Ulcer</mesh_term>
	<criteria>Patient 18 year old old . Patient diagnosis arterial , diabetic foot , venous insufficiency , pressure ulcer surgical traumatic wound . Patient 's target study ulcer/wound low extremity full thickness ulcer/wound involve tendon , capsule , bone . Patient 's target study ulcer/wound ≥1.0 cm2 ≤ 10.0 cm2 size day initial consult . Study ulcer/wound present great 6 week prior initial consult . Patients Charcot foot deformity enter long Charcot disease active , ulcer offload orthotic device . The patient adequate circulation lower extremity evidence ABI ( measure Doppler ) ≥ 0.7 . If patient noncompressible leg artery , document ABI &gt; 1.3 , patient must ToeBrachial Index &gt; 0.6 , toe pressure &gt; 50 mm Hg . Patient must adequate inhome support comply protocolmandated visit procedure , offload pressure redistribution require , proper application study product wound care regimen . Patient his/her legal representative read sign Institutional Review Boardapproved Informed Consent form Screening . An ulcer/wound ≥10.0 cm2 ≤ 1.0 cm2 size day initial consult eligible study . Patient clinical evidence gangrene infection part affect foot . The patient judge investigator study staff unable unlikely comply daily wound care instruction , study visit . Patient clinical evidence active sepsis invasive infection ( e.g. , cellulitis , osteomyelitis ) . Patient muscle , tendon , bone exposure ulcer bed . Patient known sensitivity allergy component study product Olivamine10 . Patient one medical condition ( ) , include renal , hepatic , hematologic , neurologic , immune disease opinion Investigator would make patient inappropriate candidate wound heal study . Patient malignant disease ( squamous basal cell carcinoma skin ) remission five year . Patient known alcohol drug abuse . Patient hematocrit great 60 % le 27 % . Patient 's diabetes poor control manifest HbA1c &gt; 10.0 % . Patient clinically significant renal insufficiency creatinine great 2.0 mg/dL . Patient chronic liver disease clinically significant liver enzyme abnormality evidence elevate AST , ALT , bilirubin great 1.5 time upper limit normal ( ULN ) . Patient receive oral parenteral corticosteroid , immunosuppressive cytotoxic agent , anticipated require agent course study . Patient use tobacco , expose current smoker household . Patients may participate study use tobacco 3 month smoker household 3 month . Patient use form nicotine include nicotine patch , gum , spray . Patient Acquired Immunodeficiency Syndrome ( AIDS ) know infected Human Immunodeficiency Virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>diabetic foot</keyword>
	<keyword>leg ulcer</keyword>
</DOC>